New antibody VIS649 tested in humans for first time to fight kidney disease
NCT ID NCT03719443
First seen May 14, 2026 · Last updated Jun 23, 2026 · Updated 7 times
Summary
This early-phase trial tested the safety of a new drug called VIS649 in 51 healthy volunteers. VIS649 is an antibody that blocks a protein called APRIL, which is thought to play a role in IgA nephropathy, a kidney disease. The study gave single doses of the drug or a placebo and monitored for side effects. Results will help decide if further testing in patients is warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
California Clinical Trials Medical Group
Glendale, California, 91206, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VIS649 (an antibody that blocks a protein called APRIL)
What this could lead to
If safe and effective, VIS649 could become a new treatment option for IgA nephropathy, a kidney disease that currently has limited therapies.
What could go wrong
This is a very early Phase 1 trial in healthy people, not patients. It only tests safety and dosing, not whether the drug actually works for the disease. Many drugs fail in later stages.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.